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Summary
The pharmacokinetic profile of bisphosphonates is complex
and depends on their potency in inhibiting bone resorption
through their cellular effects and on the physicochemical ac-
tion related to the interaction of these compounds with bone
matrix. Amino-substituted bisphosphonates exert a more po-
tent cellular effect on osteoclast via the inhibition of the
mevalonate pathway, whereas non-nitrogen containing com-
pounds exert a weaker effect deriving from the induction of in-
tracellular metabolites in osteoclasts. For nitrogen-containing
bisphosphonates there is a correlation between in vitro poten-
cy of inhibition of a specific enzyme, farnesyl pyrophosphate
synthase, and their antiresorptive potency in vivo. Besides
these effects on osteoclasts, bisphosphonates may in part
mediate indirectly their antiresoprtive activity through several
effects on osteoblasts and osteocytes. Different binding affini-
ties of bisphopshonates to hydroxyapatite depend on both
side chains structures and may explain how these drugs
reach bone cells and exert their prolonged action in terms of
adsorption and desorption processes. Clinical and animal-
models derived data indicate that agents with high anti-re-
sorptive potency, favourable bone binding characteristics and
good tolerability can be used with long between-dose inter-
vals to optimize therapeutic outcomes.
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Introduction
A large body of evidences collected in the last decades indi-
cates that bisphosphonates (BP) are the most potent and ef-
fective inhibitors of bone resorption in clinical use. These
agents represent the treatment of choice for postmenopausal
osteoporosis in which the BP class has consistently demon-
strated good efficacy and tolerability in reducing fracture risk, in
increasing bone mineral density and in reducing biochemical
markers of bone turnover. In clinical practice BP use has been
extended to all conditions characterised by excessive osteo-
clast-mediated bone resorption such as steroid-induced osteo-
porosis (1), Paget’s disease of bone (2) and tumour-associated
osteolysis and hypercalcemia (3). Despite this widespread clin-
ical use for more than three decades, our knowledge on phar-
macokinetic and pharmacodynamic profile of BP is still incom-
plete mainly for the technical difficulties encountered in mea-
suring their concentrations in biological fluids and for the diffi-
culty in isolating large numbers of pure osteoclasts for perform-
ing biochemical and molecular studies.
Differently from inorganic pyrophosphate, which is an endoge-
nous regulator of bone mineralization with a P-O-P structure,
BP contain two phosphonate groups linked by phosphoether
bonds to a geminal carbon atom (P-C-P structure) and this
substitution makes BP extremely stable and resistant to biolog-
ical degradation and therefore suitable for clinical use. The two
covalently-bonded groups or side chains attached to the gemi-
nal carbon, usually referred as R1 and R2, allow a wide range
of possible chemical structure.
The available BP for clinical use share some pharmacological
properties: they are poorly absorbed by intestine and are main-
ly captured by the skeleton where they bind strongly to hydrox-
yapatite crystals, suppress osteoclast-mediated bone resorp-
tion and are retained for a long time within the skeleton. All BP
are excreted unmetabolized in urine. In the traditional view the
modification of the two side chains warrants different physio-
chemical, biologic, therapeutic and toxicologic characteristics
of the different agents. According to this evidences the R1
chain represents the so called “bone hook” and the presence of
a hydroxyl (OH) group at the R1 position gives the molecule
the greatest affinity for bone (4, 5) whereas the molecular
structure at the R2 position is responsible for the antiresorptive
potency of the drug. According to the chemical structure at the
R2 chain, BP can be subdivided into “non nitrogen-containing”
BP (NN-BP) which have limited antiresoprtive potency and “ni-
trogen-containing” BP (N-BP) which share an increased antire-
soprtive potency. Modification at the R2 chain of N-BP include
lengthening the alkyl chain introducing a primary nitrogen (al-
endronate, pamidronate) and adding a tertiary nitrogen (Iban-
dronate) or heterocyclic ring (risedronate, zoledronate). Since
all N-BP have a hydroxyl group at the R1 chain, it should be ar-
gued that all the compounds in this class have the same bind-
ing affinity to bone mineral. This old view has been recently
criticized, raising the question whether the R2 structure may
contribute not only to the cellular but also to the physicochemi-
cal action of N-BP, strengthening the concept that the whole
molecule is necessary to explain the complex action on bone
and the differences observed among different N-BP.
This short review is aimed to update the molecular mecha-
nisms of action of BP and to review  recent data about the
bone binding characteristics and persistence in bone of the
agents commonly used in clinical practice.
Molecular mechanisms of action of BP: cellular effects
Effects on osteoclasts
Structurally, BP have a three-dimensional shape and are capa-
ble of chelating divalent metal ions in a bidentate manner, by
coordination of one oxygen from each phosphonate group with
the divalent cation (6). This binding is enhanced if one side
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chain is a hydroxyl or a primary amino-group, thus allowing a
tridentate interaction (7). Owing to the high affinity of BP for di-
valent ions, namely for Ca2+ ions, BP are rapidly cleared by the
circulation and avidly bind to hydroxyapatite at site of exposed
areas during active bone remodelling (8). Several evidences
performed with radiolabelled BP have shown that at pharmaco-
logical doses these agents are able to concentrate at osteo-
clast-covered bone surfaces (8). This discovery, together with
the fact that osteoclasts can internalise negatively-charged
compounds by endocytosis (9), indicate that BP are capable to
inhibit bone resorption via an intracellular effect on osteoclasts
which leads to structural cellular changes, namely the loss of
ruffled border (8). Other studies had demonstrated that BP are
incorporated by calvarial cells in vitro (10) and that after in vivo
administration BP can be visualized within endocytic vacuoles
and other organelles in osteoclasts (8, 11). Furthermore, BP
can be released from the bone surface in the acidic environ-
ment of the resorption lacuna beneath the osteoclast (8, 12).
Taken together these observations indicate that osteoclasts
are the cells in the skeleton that are most likely to be esposed
to BP and that these agents inhibit bone resorption through an
intracellular effect on osteoclasts. 
The mechanism of action of BP on osteoclastic cells has been
widely studied and the proposed mechanisms include cytotoxic
or metabolic injury of mature osteoclasts (13, 14), inhibition of
osteoclast attachment to bone (15), inhibition of osteoclast dif-
ferentiation or recruitment (16-20) or interference with osteo-
clastic structural features, namely the cytoskeleton, necessary
for bone resorptive integrity (21-23). It has been proposed that
although all BP act selectively on bone by virtue of their skele-
tal concentration, their mechanism of action may differ accord-
ing to the chemical structure (24).
Several studies suggest that NN-BP are able to induce osteo-
clast apoptosis as a consequence of the formation of intracellu-
lar metabolites in osteoclasts. These compounds can be incor-
porated into non-hydrolysable, methilene-containing analogues
of adenosine-triphosphate (ATP) reaching high concentrations
in the osteoclast cytosol (25) and thus leading to the inhibition
of various intracellular enzymes with detrimental effects on cell
function and survival. The identity of these metabolites of the
three main NN-BP, clodronate, etidronate and tiludronate, has
been estabilished by different techniques (26, 27), so that it
can be assumed that the inhibition of bone resorption induced
by NN-BP can be achieved by the unique mechanism of the in-
corporation of these agents into nucleotide analogues. As a re-
sult, this pathway causes caspase activation and apoptosis of
osteoclasts probably via the inhibition of adenine nucleotide
translocase, a component of the mitochondrial permeability
transition process (28). Furthermore, recent data underscored
that in etidronate-treated cells in vitro a caspase inhibitor,
which is able to prevent apoptosis, maintained osteoclast num-
ber and most of the bone resorption and that this effect was
maintained, to a lesser extent, when cells were treated with
clodronate (29).
Differently from NN-BP, N-BP are not metabolised in vivo (26)
thus suggesting an alternative mode of action. Available data
indicate that this class of BP acts via the inhibition of farnesil-
pyrophosphate (FPP) synthase, an intracellular enzyme of the
mevalonate pathway (6). A significant correlation has been re-
ported between the order of potency for inhibiting human FPP
synthase in vitro (either using partially purified or purified re-
combinant enzyme) (30, 31) (Table I) and the antiresorptive
potency in vivo (31). Furthermore, minor modifications of the
R2 side chains known to affect anti-resosprtive potency in vitro
were able to influence the ability to inhibit FPP synthase, thus
definitely suggesting that this enzyme is the major pharmaco-
logic target of N-BP in vivo (6).
The exact mechanism by which N-BP inhibit FPP synthase has
received further attention but has not yet fully elucidated. The
main hypothesis refers to the length and orientation of the R2
side chain which could affect the interaction of the nitrogen
group with aminoacidic residues in the active site of the en-
zyme, thus explaining why minor changes at the R2 side chain
influence the ability to inhibit FPP synthase (31, 32) markedly
affecting anti-resorptive potency (4, 33-36). Independently on
the molecular mechanism, the inhibition of FPP synthase
blocks the cellular synthesis of isoprenoid lipids required for
post-transational modification (prenylation) of small GTP-ase
signalling geranyl-geranylated proteins which are implicated in
the regulation of a variety of cell functions leading to the
arrangement of the cytoskeleton, membrane ruffling, trafficking
of intracellular vescicles and apoptosis (37-40). The loss of
prenylation of these GTP-ase signalling proteins induces an-
other characteristic effect of N-BP, namely the loss of actin
rings which represent a sort of adhesion structures, unique to
osteoclasts, and that are essential in the attachment phase pri-
or the initiation of bone resorption (41). However, the loss of
prenylation of small GTP-ases protein is probably a necessary
but not sufficient event to explain N-BP-induced osteoclast
apoptosis. In vitro studies indicate that the inhibition of bone re-
sorption induced by alendronate and pamidronate was not as-
sociated with signs of toxicity or reduction of osteoclast number
except at high concentrations (23, 42). Furthermore, it has re-
cently been reported in an experimental model that the inhibi-
tion of apoptosis by a caspase inhibitor did not prevent inhibi-
tion of bone resoprtion with alendronate and risedronate and
that the subsequent adjunct of geranyl geraniol, by restoring
geranylgeranylation, returned bone resorption to control levels
(29). These data indicate that N-BP suppression of bone re-
sorption is strictly correlated to the enzymatic inhibition with
apoptosis as a separate and possibly secondary event.
To support these observations on the mechanism of action of
N-BP, data are available on the efficacy of statins which also
inhibit the mevalonate pathway and prevent protein prenylation
in inhibiting bone resorption by rabbit osteoclasts and in mouse
calvarial cultures (43, 44), in preventing osteoclast formation in
bone marrow cultures and in inducing apoptosis of mouse os-
teoclasts in vivo (43). Similarly to statins, N-BP have been
shown to inhibit the incorporation of 14C-mevalonate into both
farnesylated and geranylgeranylated proteins in intact cells.
The same effect has been demonstrated for N-BP in purified
osteoclasts in vitro (30, 45) and in osteoclasts in vivo (46). Tak-
Table I - Values of IC50 for inhibition of human FPP synthase in vit-
ro by nitrogen-containing bisphosphonates. Data are from Dunford
et al. (31) using partially purified recombinant enzyme, or from
*Bergstrom et al. (30) using purified enzyme (nd = not determined).
In both studies, clodronate and etidronate had negligible effect on
FPP syntase activity.
Bisphosphonate IC50 (nM), IC50 (nM), 
recombinant purified recombinant
human enzyme human enzyme*
Pamidronate 200 500
Alendronate 050 340
Incadronate 030 nd
Ibandronate 020 nd
Risedronate 010 3.9
Zoledronate 003 nd
Minodronate 003 nd
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en together these observations provide definite evidence that
the enzymatic inhibition of FPP synthase with consequent loss
of protein prenylation in osteoclasts represent the major mech-
anism of action of this class of BP both in vitro and in vivo (6). 
As an alternative pathway on osteoclasts, several evidences
have been collected on a direct inhibition by BP on different hy-
drolytic enzymes such as metalloproteases (47). This adjunc-
tive mechanism may contribute to explain the overall inhibition
of bone resorption since this process finally requires proteolytic
degradation of bone matrix proteins. On the other hand, this
mechanism may be at least in part responsible for the benefi-
cial effect of BP in animal models of cartilage matrix damage in
which cartilage degeneration was prevented when animals in-
jected with chymopapain were pre-treated with zoledronic acid
(48). Finally, BP can also inhibit protein tyrosine phosphatases
which are essential for both osteoclast formation and osteo-
clastic resorptive activity (49), but the lack of correlation be-
tween this inhibition and the anti-resorptive potency leads to
the potential conclusion that this is not the major mechanism
by which these agents inhibit bone resorption in vivo (6). 
The finding of the inhibition of osteoclast-like cells formation by
BP in long-term cultures of human bone marrow (18) raised the
question of a possible indirect inhibition of bone resorption by
BP as a direct effect on mononuclear osteoclast precursors
with prevention of osteoclast formation. To this respect, data
have been published on a paradoxical increase in osteoclast
number following BP administration as a possible consequence
of a transient increase in PTH which in turn increases osteo-
clast recruitment (50). Later studies came to the conclusion
that BP inhibit bone resorption without affecting osteoclast for-
mation in vitro, suggesting that these agent act primarily on
mature cells rather than on osteoclast precursors (42, 51, 52).
Effects on osteoblasts and osteocytes
Several reports have been focused on the effects of BP on os-
teoblasts and osteocytes indicating that these agents can stim-
ulate the formation of osteoblasts precursors and of mineral-
ized nodules in murine and human bone marrow cultures in vit-
ro and can promote early osteoblastogenesis in mice in vivo
(53). Moreover, etidronate promotes osteoblast differentiation
in rat calvaria (54) and neridronate increases the proliferation
of human osteoblastic cell in cultures (55). It has been shown
in primary human trabecular cultures that both alendronate and
risedronate increase osteoblast and osteoblast progenitor num-
bers (56). BP are believed to attenuate osteoblast and osteo-
cyte apoptosis by activating extracellular signal-regulated ki-
nases with anti-apoptotic activity (57). Further studies indicate
that the prevention of osteocyte apoptosis is dose-dependent,
is independent of the chemical structure of the BP, and is sec-
ondary to BP-induced opening of connexin 43 hemichannels at
cellular level and that these effects  are fully dissociable from
the ability to inhibit FPP (58). Finally, in mice receiving gluco-
corticoids BP administration prevented glucocorticoid-induced
osteoblast apoptosis (59). Since osteocyte and osteoblast via-
bility might contribute to the maintenance of the mechanical
competence of the skeleton, independently on bone mineral
density (60), the effectiveness of BP in metabolic bone dis-
eases may result, at least in part, from these actions on bone
forming cells. However, since it is not known whether BP can
directly affect osteoblastogenesis and osteocyte viability in vi-
vo, the importance of these effects in humans remains to be
fully elucidated.
Since the development of osteoclasts is controlled by osteo-
clastogenic factors synthesized by osteoblasts and bone mar-
row osteoblastic/stromal cells secrete the main components of
the signalling pathway of the osteoprotegerin/RANK/RANK-lig-
and system, attention has been focused on the possible inter-
actions between BP and the modulation of osteoclastogenesis
driven by these mediators. Recent studies have shown that BP
can decrease RANK-L mRNA expression in a rat osteoblast
cell line (61) and increase osteoprotegerin mRNA and protein
expression in human osteoblasts (62). These results were re-
cently confirmed in a clinical study performed in a small group
of postmenopausal women with osteoporosis in which alen-
dronate and risedronate-treated patients had significantly in-
creased serum levels of osteoprotegerin versus controls after 6
and 12 months of treatment which were positively correlated to
changes in bone mineral density (63), whereas serum levels of
RANK-L did not change throughout the treatment period.
These data are in agreement with a previous in vitro study indi-
cating that zoledronate may inhibit bone resorption by reducing
transmembrane RANK-L expression and increasing osteopro-
tegerin secretion in osteoblastic-like cells leading to a de-
creased capacity of osteoblastic-like cells to support osteoclast
formation (64). Taken together, these data strongly support the
hypothesis that BP may indirectly mediate their antiresorptive
activity through their action on osteoblasts.
Interactions with bone matrix
The clinical relevance of the cellular actions of BP derived from
recent research data has limited the interest into their physico-
chemical properties. However, different skeletal binding proper-
ties among BP in healthy humans and in different clinical con-
ditions can affect the pharmacokinetic of the individual com-
pound thus influencing distribution to bone and long-term
skeletal retention of these agents. This in turn can have clinical
and therapeutic consequences in term of efficacy and persis-
tency of action of the administered BP. Previous studies indi-
cated that the presence of a OH group in R1 side chain in-
creases the binding capacity to hydroxyapatite (HAP) and that
this property was independent on the structure of the R2 side
chain (4, 65). However, a recent in vitro study, employing a
crystal growth method to assess the kinetic affinity constant of
different BP, demonstrated the existence of significant differ-
ences in terms of affinity among hydroxyl-substituted BP, thus
contributing to the hypothesis that the R2 chain is crucial not
only for the cellular action but also for the physicochemical ef-
fect of the individual compound (66).
In theory, the amount of BP captured by the skeleton in vivo
depends not only on its affinity for HAP but also on renal func-
tion and prevalent rate of bone turnover (67). In conditions of
normal renal function and at a theoretical uniform level of bone
turnover, informations about the amount of BP attached to the
skeleton can be derived from urinary data. By subctracting the
amount excreted in a 24-hour urine collection after intravenous
administration, the whole body retention of the BP can be cal-
culated. By this method, the retention of risedronic acid in
healthy volunteers appears lower than that of other N-BP (alen-
dronate and zoledronate), but the clinical significance of these
findings has to be considered with caution since data were ob-
tained in patients affected by different clinical conditions (68,
69). A partial support to the hypothesis of different binding
affinity among N-BP comes from the only head to head report
ever published using labelled risedronate and alendronate in
humans at bio-equivalent doses. In this study after 72 hours a
significant less amount of risedronate than alendronate had
been retained, thus accounting for a different binding affinity of
the two molecules (70). The clinical relevance of these obser-
vations is still debated, but is consistent with the observed ef-
fects on the more rapid rate of increase of biochemical markers
of bone resorption after withdrawal in large clinical trials per-
formed with risedronate as compared to alendronate (71, 72).
Furthermore, a recent head to head clinical trial showed that
weekly alendronate determined a statistically significant 1.3 to
1.4-fold greater mean reduction of bone turnover markers than
did weekly risedronate at common clinically used dosages (73).
This difference would not be predicted by comparison of the ef-
fects on bone resorption of these N-BP in the rat in which rise-
dronate is up to three-fold more potent. Again, these data are
consistent with the reported significant difference of approxi-
mately 35% in kinetic binding affinities for HAP for risedronate
and alendronate in a model of HAP crystal growth method (66).
The dependency of bone attachment of BP on bone turnover
has been extensively demonstrated by a study on labelled al-
endronate localisation in rat bone demonstrating that after ad-
ministration the BP binds to exposed hydroxyapatite surfaces
at sites prepared for undergoing bone resorption (8). Conse-
quently, retention and subsequent release depend on available
binding sites so that pharmacokinetics are likely to differ in vari-
ous pathophysiological conditions. Furthermore, the amount of
BP retained in the skeleton is also supposed to vary markedly
between patients, particularly in diseases with relatively high
interindividual variation in bone turnover such as Paget’s dis-
ease of bone where retention has been reported between 10
and 90% (74). In osteoporosis the variability is less, ranging for
intravenous pamidronate between 47% and 74% (75). Data on
BP retention in the same patients after repeated administration
have not been published, but Cremers reports a personal ob-
servation of a intrapatient variation in skeletal retention of the
administerd BP not exceeding the 7% over a period of one
year (67). Taken together, these observations suggest that the
variability in skeletal retention across different clinical condi-
tions and the interindividual variability play a crucial role in
terms of biological effects and may account for differences in
treatment response.
Differently from previous studies which by competitive binding
approaches demonstrated only small differences (65, 76) or no
significant differences (4, 77) in affinities among different N-BP,
a recent study using a more sensitive HAP crystal growth
method to determine the kinetic binding affinities of BP ranked
the studied compounds according to their binding affinities as
follows: zoledronate > alendronate > ibandronate > risedronate
> etidronate > clodronate with a significant difference for the
affinity constants (Table II) (66). This study took into account
the effects of these BP also on other HAP surface properties
potentially affecting the mineral binding of these agents in vivo
such as zeta potential and interfacial tension. HAP zeta poten-
tial is the electrical potential at the crystal surfaces and it is in-
fluenced by local pH. Since it is suitable to change after the ad-
sorption of highly charged anions such as BP (78-81), zeta po-
tential may influence the subsequent binding of charged mole-
cules. The observed changes in zeta potentials in the presence
of different BP are likely to be related to the degree of protona-
tion of the nitrogen moiety on the R2 side chain and this can
account for the variable capacity of any given surface region of
bone mineral to absorb different BP (66). Interfacial tension ex-
presses the solid/liquid interfacial properties and plays an im-
portant role in the adsorption of molecules at solid/solution in-
terfaces. It has been shown that HAP interfacial tension de-
creases with increasing BP binding and that the order of de-
creasing was similar to that of the affinity constants with the on-
ly difference of the interchanged position of etidronate and rise-
dronate (66). Taken together these observations suggest that
the differences among BP in terms of their effects on zeta po-
tentials and interfacial tension may have relevance for BP inter-
actions with the bone matrix (66) even if the clinical signifi-
cance of these findings at present is still unclear (82).
Available data on relative binding affinities of BP for human
bone may explain differences in the recovery of bone resorp-
tion after BP therapy has been stopped. Published data sug-
gest that for etidronate given cyclically (83) and for daily rise-
dronate (71) bone turnover returns to basal values within one
year after withdrawal, whereas zoledronate induces a sus-
tained inhibition of bone resorption for at least one year after a
single intravenous dose of 4 mg (84). Oral alendronate given at
10 mg/day for 5 years shows an apparently long persistence
with a suppression of bone resorption for up to 5 years after
stopping (85). The variable persistence of the effects after with-
drawal may reflect differences among BP in terms of their
affinities for mineral binding but the clinical relevance of these
data needs to be interpreted with some caution since this re-
sponse can be influenced by the dose given and by differences
in terms of basal turnover of the populations under study. Final-
ly, and more importantly, no data have been published from
head to head studies with different BP. 
Studies on binding affinities of BP may provide important infor-
mations about how these drugs reach bone cells and exert
their prolonged action in terms of adsorption and desorption
process. To this respect, lower affinity BP exhibit a lower up-
take, a higher desorption with a lower re-attachment and are
embedded in bone in a more diffused fashion, whereas higher
affinity BP are characterised by avid uptake, a lower rate of
desorption with a higher re-attachment and a higher concentra-
tion in solution locally in the vicinity of bone cells (66). This
model raises another intriguing question related to the activity
and the fate of sequestred BP released by remodelling since it
is not known whether and to what extent this amount of re-
leased compound will be pharmacologically active and furtherly
able to suppress bone resorption. Several clinical studies per-
formed with different BP indicated that withdrawal after pro-
longed periods of treatment was not associated with a rebound
increase of bone turnover and rapid bone loss (71, 72, 86-89)
as it was commonly seen after cessation of hormone replace-
ment therapy (90). Taken together, these observations can
support the hypothesis that amounts of the embedded BP
which has been released from the skeleton are still pharmaco-
logically active at bone surface but definitive data are lacking
and no conclusions can be drawn about differences among in-
dividual agents (82).
Conclusions
The pharmacokinetic profile of BP is complex and depends on
their cellular effects and on the physicochemical action related
to the interaction with bone matrix. To this respect, pharmaco-
kinetic models must take into account several variables such
as the potency of single agents in inhibiting bone resorption
and the amount of BP bound to the skeleton and their long-
term skeletal retention. Most clinical pharmacokinetic studies
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Table II - HAP adsorption affinity constants of different bisphospho-
nates at pH 7.4.
Bisphosphonate KL/106 L mol–1
Clodronate 0.72 ± 0.12*
Etidronate 1.19 ± 0.10*
Risedronate 2.19 ± 0.17
Ibandronate 2.36 ± 0.32
Alendronate 2.94 ± 0.24*
Zoledronate 3.47 ± 0.18*
* Significantly different from risedronate KL (P<0.05) (from Nancollas et al. –
ref. 66).
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have used noncompartimental models but attempts are in
progress to better define the pharmacokinetic of these agents
by compartimental models taking into account the distribution
of the drug not only in serum and bone surface but also in deep
bone (75). Further pharmacokinetic/pharmacodynamic models
have been developed taking into account a fourth compartment
related to the time course of biochemical markers of bone re-
sorption (91). These models have actual limitations since they
have not been validated prospectively in different metabolic
bone diseases and differences in binding and release of the in-
dividual agents from the skeleton, in oral bioavailability and in
renal excretion make it necessary to calculate a separate phar-
macokinetic profile for every individual BP (67). 
From a clinical point of view, several studies published in re-
cent years confirmed that a weekly administration of equipo-
tent doses alendronate and risedronate can be as effective as
daily dosing in maintaining bone mineral density and in reduc-
ing bone turnover over one or two years in large samples of
postmenopausal women with osteoporosis (92, 93). According
to this pharmacokinetic profile, the administration at increased
drug-free intervals of high-dose BP requires agents with high
anti-resorptive potency, favourable bone binding characteris-
tics and good tolerability. This opportunity has been explored
by recent studies reporting that in animal models the effects of
Ibandronate depends on the total dose irrespective of the
drug-free interval (94). The importance of the total dose con-
cept has been recently confirmed in a clinical study which for
the first time reported that intermittently administered Iban-
dronate given with a between-dose interval of more than 2
months has a prospectively demonstrated significant antifrac-
ture efficacy over 3 years in postmenopausal women with os-
teoporosis (95). Data presented at the ASBMR 28th Meeting
on the effect of once-yearly infusion of zoledronic acid 5 mg
on spine and hip fracture reduction in postmenopausal women
with osteoporosis reinforce this hypothesis (96), thus demon-
strating the viability of less frequent dosing of BP with poten-
tial benefits in terms of therapeutic outcome and patient ad-
herence to treatment.
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